Introduction {#S0001}
============

*Mycobacterium tuberculosis* (MTB) and *Mycobacterium bovis* are the most important members of *M. tuberculosis* complex (MTBC).[@CIT0001] They are known as causative agents of tuberculosis (TB), which infects almost one third of the global population.[@CIT0002] The TB incidence is moderate in Iran as a fairly large country (14 per 100,000 people), but is high in neighbor countries such as Turkmenistan, Afghanistan and Pakistan.[@CIT0002],[@CIT0003] Running the national TB control programs in the recent decades, incidence of TB has decreased dramatically in Iran, but it has remained high in some regions such as Golestan province (32.1 per 100,000).[@CIT0004] Emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) isolates can result in complicated as well as costly treatment regimens and is attributed to the failure of the implementation of proper TB control strategies.[@CIT0005] In this situation, reliable and timely drug susceptibility testing using conventional and molecular methods have an essential role for diagnosis of MDR isolates.[@CIT0006]

Pyrazinamide (PZA) is one of the most critical drugs for treatment of drug-susceptible and MDR-TB. Despite including PZA as a first-line drug for TB treatment, assessment of its in vitro activity against MTB isolates is technically difficult because PZA is only active at acidic pH. Hence, the pyrazinamidase (PZase) test, also known as the Wayne test, was introduced as simple method for PZA drug susceptibility testing (DST).[@CIT0007]

Studying the molecular epidemiology of MTBC isolates could assist TB control programs through understanding the predominant MTBC genotypes and their transmission dynamics within the population.[@CIT0008] Spacer oligonucleotide typing (spoligotyping) is an approach that is widely used for exploring the genotypic structure of MTBC isolates because it is simple, rapid, and requires a very low amount of DNA.[@CIT0009],[@CIT0010]

Golestan province is situated in the north of Iran in the vicinity of the Caspian Sea and Turkmenistan country. We previously reported that Golestan province has received a large number of immigrants by inter-province movement and from neighbor countries such as Afghanistan and Turkmenistan.[@CIT0011] Within this context, the present study aimed to explore the circulating spoligotypes, drug resistance rate to PZA and to identify the mutations conferring resistance to rifampin (RMP) and isoniazid (INH) in MTBC isolates in Golestan province.

Materials and Methods {#S0002}
=====================

Isolates Collection {#S0002-S2001}
-------------------

The study proposal was approved by the ethics committee of Tehran University of Medical Sciences. A cross-sectional epidemiological study was carried out for the pulmonary TB suspected cases living in Golestan province, from July 2014 to July 2015. The patients who were culture positive for MTB were included in this study. All isolates were collected during routine procedures at the Tuberculosis Reference laboratory, Golestan, Iran, and no samples were specifically collected for this research. Patients with extrapulmonary TB and culture negative pulmonary TB cases were excluded. The 11,807 clinical specimens were collected from diagnosed cases during this study and 166 clinical isolates were recovered from new (n=164) and previously treated (n=2) TB cases in Golestan province (one isolate per patient) and included in this study. The identification of the isolates was performed according to the standard microbiologic procedures.[@CIT0012]

Drug Susceptibility Testing {#S0002-S2002}
---------------------------

DST to first-line anti-TB drugs; rifampin (RMP; 40 μg/mL), isoniazid (INH; 0.2 μg/mL), ethambutol (ETL; 2 μg/mL) and streptomycin (STM; 4 μg/mL) was performed for all isolates on Lowenstein-Jensen (LJ) medium using proportional method. MDR isolates were further subjected for second-line anti-TB drugs; ciprofloxacin (CIP; 2 μg/mL), ofloxacin (OFX; 4 μg/mL), ethionamide (ETD; 40 μg/mL), kanamycin (KAN; 30 μg/mL), capreomycin (CAP; 40 μg/mL), cycloserin (CYN; 30 μg/mL), *para*-aminosalicylic acid (PAS; 1 μg/mL) (all from Sigma, USA) and amikacin (AMK; 30 μg/mL) (Exir, Iran) on the LJ medium via the proportional method and susceptibility testing for levofloxacin (LVX; 1 μg/mL) (Sigma, USA) performed on Middlebrook 7H10 agar media (BBL Microbiology Systems, Cockeysville, MD, USA).[@CIT0012],[@CIT0013] Reference strain MTB H37Rv was used for quality control.

PZase (Wayne) Test {#S0002-S2003}
------------------

PZase activity was determined using Wayne technique,[@CIT0007],[@CIT0014] in Middlebrook 7H10 medium containing albumin dextrose catalase (ADC) growth supplement (BBL Microbiology Systems, Cockeysville, MD, USA), 100 μg/mL PZA and 2 mg/mL sodium pyruvate (Sigma, United States). Briefly, isolates cultured in the LJ medium, then a heavy suspension of each isolate inoculated onto the two tube of Middlebrook 7H10 agar, and incubated at 37°C. One milliliter of freshly prepared 1% ferrous ammonium sulfate solution (Merck, Germany) was introduced into one of the test tubes after 4 days of incubation. A positive PZase activity appeared as a pink-brown band on the agar surface.[@CIT0015] In the case of the absence of the pink-brown ring, the second tube was tested after additional two days of incubation. The MTB strain H37Rv and *M. bovis* used as PZase positive and negative control, respectively.

PCR and Sequencing {#S0002-S2004}
------------------

The three loci (*rpo*B, *kat*G and *inh*A) were amplified by PCR using locus-specific primers, followed by agarose gel electrophoresis of amplicons.[@CIT0005],[@CIT0016] The amplicons were subjected to sequencing (Macrogen, Korea) and the sequences were compared with the deposited sequences for MTB strain H37Rv using the BLAST. The sequences have been deposited in GenBank and provided accession numbers were documented.

Spoligotyping {#S0002-S2005}
-------------

Genomic DNA for 166 MTBC isolates was extracted from fresh sub-cultures.[@CIT0017] Spoligotyping was carried out using the commercially available kit (Mapmygenome, India) according to the standard protocol.[@CIT0018] MTB strain H37Rv and *M. bovis* strain BCG were used as positive control and distilled water as a negative control. Distribution of the isolates into different genotypes was performed using the SITVITWEB database ([<http://www.pasteur-guadeloupe.fr:8081/SITVIT2/batch.jsp>]{.ul}).[@CIT0019]

Definitions {#S0002-S2006}
-----------

In the SITVITWEB database, spoligotype international type (SIT) represents spoligotype shared by two or more isolates, whereas patterns reported for a single isolate designates as "orphan".[@CIT0019] Isolates sharing identical spoligotyping patterns were categorized as "clusters" and the pattern was called "unique", if the spoligotype patterns correspond to only one isolate.[@CIT0011] Isolate that was resistant to at least one anti-TB drugs was defined as "any drug resistant". MDR-TB is defined as isolates that resistant to both INH and RMP, while XDR-TB is defined as MDR-TB that is resistant to any fluoroquinolone and at least one of injectable second-line drugs (AMK, KAN or CAP).[@CIT0005]

Statistical Analysis {#S0002-S2007}
--------------------

Data analysis was performed using SPSS ver. 22 (SPSS Inc., Chicago, IL, USA). Descriptive analysis of the data was conducted using frequencies (counts). For comparison of the categorical variables, the Fisher's exact test was used at *p* \<0.05.

Results {#S0003}
=======

Demographic Information {#S0003-S2001}
-----------------------

A total of 166 clinical MTBC isolates (164 MTB and 2 *M. bovis*) were obtained from pulmonary TB patients and included in this study. The majority of isolates (n=150, 90.4%) were recovered from sputum while 15 (9%) were from bronchoalveolar lavage and only one isolate (0.6%) was obtained from gastric juice. The average age of patients were 50.4 ± 19.5 years and 59.6% (n= 99) were male. The 158 (95.2%) patients were Iranian whereas 8 (4.8%) were foreign immigrants.

Drug Susceptibility Patterns {#S0003-S2002}
----------------------------

The set of 148 (89.2%) isolates were susceptible to all first-line anti-TB drugs, and 18 (10.8%) were found to be any drug resistant, including; two (1.2%) MDR, three (1.8%) INH monoresistant, 12 (7.2%) STM monoresistant, and one isolate (0.6%) that resistant to INH and STM. In addition to the phenotypic DST for second-line anti-TB drugs was completed on two MDR isolates and both were resistant to ETL, but one of them showed resistance to CIP, OFX, LVX, AMK and KAN.

Resistance to PZA {#S0003-S2003}
-----------------

As *M. bovis* is naturally resistant to the PZA, then PZase test was conducted for 164 MTB isolates. Among them, four (2.4%) were resistant to PZA, including two MDR and two non-MDR isolates.

Mutations in *rpo*B, *kat*G and *inh*A Loci {#S0003-S2004}
-------------------------------------------

The analysis for rifampin resistance-determining region (RRDR) of *rpo*B loci for two MDR isolates showed that both had Ser531Leu substitution (TCG→TTG) (GenBank accession nos. MG490375 and MG697230). We analyzed *inh*A and *kat*G loci for six INH resistant isolates, four isolates (66.7%) had Ser315Thr substitution (AGC→ACC) in *kat*G gene (GenBank accession nos. MG461957, MG461959, MG461960 and MG490376) and one (16.7%) cytosine-to-thymine transition \[C(−15)T\] was detected at the nucleotide positioned 15 bases upstream of the start codon within the *inh*A promoter region (GenBank accession no. MH373357). One INH-resistant isolate had not mutation at *kat*G and *inh*A loci, and termed as wild type. Identified mutations and relevant accession nos. in GenBank were summarized in [Table 1](#T0001){ref-type="table"}.Table 1Identified Mutations for *rpo*B, *kat*G and *inh*A Loci in *Mycobacterium tuberculosis* Complex Isolates, and the Relevant GenBank Accession NumbersIsolate NumberPhenotypic ResistanceMutationAccession Number21INH*kat*G-wild typeMG438288*inh*A-\[C(−15)T\]MH37335757INH*kat*G-315 AGC→ACC (Ser→Thr)MG461957*inh*A-wild typeMH74437067INH*kat*G-wild typeMG461958*inh*A-wild typeMH744371153INH*kat*G-315 AGC→ACC (Ser→Thr)MG461959*inh*A-wild typeMH744372165INH and RMP*kat*G-315 AGC→ACC (Ser→Thr)MG461960*inh*A-wild typeMH744373*rpo*B-481 ACC→ AGC (Thr→ Ser)\
*rpo*B-531 TCG→ TTG (Ser→Leu)MG697230166INH and RMP*kat*G-315 AGC→ACC (Ser→Thr)MG490376*inh*A-wild typeMH744374*rpo*B-531 TCG→ TTG (Ser→Leu)MG490375

Spoligotyping Family Distribution {#S0003-S2005}
---------------------------------

A total of 139 (83.7%) isolates were represented by 28 SITs. The most frequent genotypes were; SIT127/Ural-2 (n=25, 15.1%), SIT1/Beijing (n=21, 12.7%), SIT3427/Ural-2 (n=18, 10.8%), SIT21/CAS1-Kili (n=11, 6.6%), SIT25/CAS1-Delhi (n=10, 6%), SIT357/CAS1-Delhi (n=10, 6%), and 27 isolates (16.3%) displayed orphan patterns ([Figure 1](#F0001){ref-type="fig"}). MDR isolates shared SIT-1/Beijing spoligotype and the detailed information about assigned spoligotypes with respect to drug resistance pattern were described in [Table 2](#T0002){ref-type="table"}.Table 2Association Between Identified *Mycobacterium tuberculosis* Complex Genotypes and Drug Resistance Patterns of 166 *M. tuberculosis* Isolates in Golestan ProvinceLineageSITn (%)Spoligotype PatternResistance Pattern No.RMP, INH, ETL and STMINH and STMINHSTMBeijing121 (12.7)□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■2\--5Ural-212725 (15.1)■□■■■■■■■■■■■■■■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--342718 (10.8)■□□■■■■■■■■■■■■■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\--23611 (0.6)■□■■■■■■■■■■□■■■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--Ural-12622 (1.2)■■■■■■■□□■■■■■■■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--15682 (1.2)■■■■■■■□□■■■■■■■■■□■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--CAS1-Delhi2510 (6)■■■□□□□■■■■■■■■■■■■■■■□□□□□□□□□□□□■■□□■■■■■\-\-\--35710 (6)■■■□□□□■■■■■■■■■■■■■■■□□□□□□□□□□□□□□■■■■■■■\-\--310928 (4.8)■■■□□□□■□■■■■■■■■■■■■■□□□□□□□□□□□□■■■■■■■■■\-\-\--7546 (3.6)■□■□□□□■■■■■■■■■■■■■■■□□□□□□□□□□□□■■■■■■■■■\-\-\--264 (2.4)■■■□□□□■■■■■■■■■■■■■■■□□□□□□□□□□□□■■■■■■■■■\-\-\--27832 (1.2)■■■□□□□■■■■■■■■■■■■■■■□□□□□□□□□□□□■■■■■■□■■\-\-\--26931 (0.6)■■■□□□□■■■■■■■□□■■■■■■□□□□□□□□□□□□■■■■■■■■■\-\-\--11981 (0.6)■■■□□□□■■■■■□■■■■■■■■■□□□□□□□□□□□□■■□□■■■■■\-\-\--CAS1-Kili2111 (6.6)■■■□□□□■■□■■■■■■■■■□□□□□□□□□□□□□□□□■■■■■■■■\-\-\--CAS31612 (1.2)■■■□□□□■■■■■■□□□□■□□□□□□□□□□□□□□□□□□■■■■■□□\-\-\--O-12 (1.2)■■■□□□□■■■■■■■■■■■□□□□□□□□□□□□□□□□□■■■■■■■■\-\-\--O-21 (0.6)■■■□□□□■□■■■■■■■■■□□□□□□□□□□□□□□□□■■■■■■■■■\-\-\--CAS22881 (0.6)■■■□□□□□□□■■■■■■■■■■■■□□□□□□□□□□□□■■■■■■■■■\-\-\--T1533 (1.8)■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■\-\-\--1721 (0.6)■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□□■■■■■■■\-\-\--2841 (0.6)□□□□■■■■■■■□□■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■\-\-\--5201 (0.6)■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■□■■■■■\-\--1T2521 (0.6)■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■□■■■\-\-\--37761 (0.6)□□□□■■■■■■■□□■■■■■■■■■■■■■■■■■■■□□□□■■■□■■■----\--EAI272 (1.2)■■■□□□□■■■■■■■■■■■■■■■□□■■■■■■■■■□□□□■■■■■■\-\-\--H35111 (0.6)■■■■■■■■■■■■■■■■■■■■■□□□□□□□□□□■□□□□■■■■■■■\-\-\--Turkey411 (0.6)■■■■■■■■■■■■■■■■■■■□□□□□■□□■■■■■□□□□■■■■■■■\-\-\--BOV_14821 (0.6)■■□■■■■■□■■■■■■□■■■■■■■■■■■■■■■■■■■■■■□□□□□\--1-11811 (0.6)■■□■■■■■□■■■■■■□■■■■■■□■■■■■■■■■■■■■■■□□□□□\-\-\--Not definedO-33 (1.8)■■■■■■■■■■■■□■■■■■□■■■■■■■■■■■■■□□□□■■■■■□□-11-O-43 (1.8)■□■□□■■■■■■■■■■■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--O-52 (1.2)□■■□□□□□■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■\-\-\--O-61 (0.6)■■■□□□□■■■■■■■■■■■■■■■■□□□□□□□□□□□□□□□□□□□□\-\-\--O-71 (0.6)■■■□□□□■■■■■■■■■■■■■■■□□□□□□□□□□□□□□■■■■□■■\-\-\--O-81 (0.6)■■■□□□□■■■■■■■■■■■■□□□□□□□□□□□□□□□□□□□□□□□■\-\-\--O-91 (0.6)■■■■■■■■■■■■■■■■■■■■■■□□■■■■■□□□□□■■■■■■■■■\-\-\--O-101 (0.6)■■■■■■■■■■■■■■■■■□■■■□■■■■■■■■■■□□□□■□■□■■■\-\-\--O-111 (0.6)■■■□□□□■■■■■■■□□□□■□□□□□■■■■■■■■■□□□■■■■■■■\-\-\--O-121 (0.6)■■■□□□□■■■■■□■■■■■■□■■□□□□□□□□□□□□□□□□□□□□□\-\--1O-131 (0.6)■■■□□□□■□■■■■■■■■■■■■■□□□□□□□□□□□□□□□□□□□□□\-\-\--O-141 (0.6)■□■■■■■■□■■■■■■■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--O-151 (0.6)■□■■□■■■■■■■■■■■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--O-161 (0.6)■■■■■■■■□□□■■■■■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--O-171 (0.6)■□■□□□□■□■■■■■■■■■■■■■□□□□□□□□□□□□■■■■■■■■■\-\-\--O-181 (0.6)■□□■■■■■■■■■■■□■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--O-191 (0.6)■□□■■■■■■■■■□■■■■■■■■■■■■■■■□□□■□□□□■■■■■■■\-\-\--O−201 (0.6)■□□■■■■■■■■■□■■■■■■■■■■■■■■■□□□■□□□□■■■□■■■\-\-\--O-211 (0.6)■■■■■■□□□□□□□□□□□□■■■■■■■■■■□■■■□□□□■■■□■■■\--1-[^1] Figure 1The *Mycobacterium tuberculosis* complex genotypes identified in the studied population.

Among the 166 MTBC isolates, a total of 49 different patterns were detected; 136 isolates were distributed into 19 clusters and the remaining (n=30) had unique patterns. The largest cluster corresponded to the SIT127 (n=25), followed by SIT1 (n=21) and SIT127 (n=18).

Discussion {#S0004}
==========

Using spoligotyping method, the large variety of MTBC genotypes was identified in Golestan province. The overall population structure of MTBC isolates in Golestan province is dominated by the CAS family (including CAS1-Delhi, CAS1-Kili, CAS and CAS2), that corresponded to one-third of the studied isolates. As mentioned in the previous study,[@CIT0011] Golestan province receives large numbers of immigrants, especially from Sistan and Baluchestan province (south of Iran) and Afghanistan country. Moreover, demographic investigations showed that most of the CAS family isolates were obtained from patients who migrated from Sistan and Baluchestan province. In 2013, Haeili et al,[@CIT0020] reported that 57% of isolates in Sistan and Baluchistan province belonged to the CAS family. It is important to mention that the CAS/Delhi genotype is ubiquitously prevalent in Iran's neighboring countries such as, Saudi Arabia, India, Pakistan, and Afghanistan.[@CIT0021],[@CIT0025] Therefore, it is likely that the CAS/Delhi family was disseminated to Iran through frequent migration and travel between the boundaries.

Ural-2 was found as the second most common genotype in the current study, that was assigned as NEW-1 genotype, based on the MIRU-VNTR*plus* database.[@CIT0026] Ural-2 has earlier been reported with high prevalence from Tehran (capital of Iran) and Khorasan (eastern neighbor of Golestan province),[@CIT0027],[@CIT0028] indicating that this genotype was abundant in Iran and reported with a much lesser extent in Kyrgyzstan and Kazakhstan countries.[@CIT0029],[@CIT0030] The current study confirms the previous theory that mentioned Ural-2 is endemic for Iran.[@CIT0031]

The Beijing family was found to be particularly prevalent in Golestan province, and has been associated with any drug resistance pattern as well as two MDR isolates. It has been shown that Beijing isolates were associated with MDR and XDR-TB in several studies.[@CIT0032],[@CIT0033] Beijing is known as common genotype circulating in the countries located in northern Iran (Kazakhstan, Georgia, and Russia) and countries located in Central and Eastern Central Asia.[@CIT0029],[@CIT0032],[@CIT0034],[@CIT0035] Therefore, the presence of this genotype in Golestan province can be attributed to the migration and traffic of the people from the mentioned countries to this geographical region.

In this study, Ural-1 and T1 family were found with a lower percentage. In Iran, Ural-1 and T1 family, were previously found with percentages of 1--16% and 2.1--13% in various regions of Iran,[@CIT0020],[@CIT0027],[@CIT0028],[@CIT0036],[@CIT0038] which could indicate a relatively uniform scattering of them in different parts of the country.

In this study we find orphan isolates belonged to cluster that we named as Orphan-4, which shared by three clinical isolates. Their fingerprints were closely related to SIT127, but differ in spoligospacers four and five. Thus, to the best of our knowledge, this could be evidence for active evolution of SIT127/Ural-2 in Golestan province. In addition to Orphan-4, in this study we found four new orphan clusters (Orphan-1, Orphan-3, and Orphan-5). Surprisingly, we found that Orphan-3 was associated with drug resistance, as two out of three isolates were INH resistant but other clusters were pansusceptible.

In the present study, spoligotyping patterns of 27 isolates did not match the patterns available in SITVITWEB database, suggesting the high evolutionary pressure on the circulating isolates (as mentioned for Orphan-4) and/or presence of new spoligotypes specially for Orphan-1, Orphan-3, and Orphan-5 clusters in this region.

Golestan province is one of the main ranch areas in Iran, and finding two *M. bovis* isolates is a reminder for zoonotic nature of bovine TB. Despite the efforts that made for *M. bovis* eradication, it has not yet been completely controlled in Iran. As one of *M. bovis* isolates was resistant to INH, a comprehensive study must be conducted in order to assess the antibiotic resistance pattern and epidemiology of bovine TB in this province.

In this study, gene regions with resistance-associated mutations of *kat*G, *inh*A and *rpo*B were amplified using locus-specific primers. The results of sequencing for INH resistant isolates showed that 83% of them had mutations in the codon 315 of *kat*G or promoter region of *inh*A genes. According to the results of the present study, mutation in the codon 315 was reported in the previous studies conducted in Iran and other countries with the percentages of 27-- 97.5%.[@CIT0005],[@CIT0016],[@CIT0039],[@CIT0042] Then, it is considered that mutations in the *kat*G are the most important reason for the INH resistance in MTBC isolates, and the mutation in the *inh*A gene has a minor role. Moreover, one isolate was wild type at both loci, which may have other mechanisms for INH resistance, such as mutation at the *oxy*R-*ahp*C promoter regions, *kas*A or *ndh* loci.

It was well established that mutations within the RRDR of *rpo*B locus occur in more than 95% of RMP-resistant isolates. In this study, both MDR isolates had Ser531Leu mutations in *rpo*B gene. Mutation in codon 531 was frequently reported by studies from Iran, Pakistan, and Egypt, as the most predominant mutation responsible for RMP-resistance.[@CIT0005],[@CIT0043],[@CIT0044] In addition, studies conducted in other countries have shown that mutation in codon 531 corresponded with 29--79% of RMP-resistant phenotype.[@CIT0016],[@CIT0045],[@CIT0046] Furthermore, we found Thr481Ser substitution that was never reported previously, and further studies are required to definitively characterize its role in RMP resistance.

In this study, we found an MDR isolate that was simultaneously resistant to fluoroquinolones and second-line injectable drugs, determined as XDR-TB. To the best of our knowledge, this was the first report of XDR-TB in Golestan province. DST for second-line drugs was studied in different parts of Iran and resistance varied from 11.1--100%.[@CIT0005],[@CIT0047],[@CIT0049] Although the use of first-line drugs was effective for treatment of TB, the emergence of drug-resistant isolates has reduced the efficacy of the standard regime and becomes a major constraint for TB control programs. Emergence of MDR and XDR isolates is a significant barrier for TB control, and it is important to ensure that patients receive effective treatment. Moreover, future epidemiological studies must be designed for determining the transmission root of drug-resistant isolates in this region.

Assessment of PZase activity of MTB isolates using the Wayne method showed that the resistance to PZA was low in the drug susceptible isolates, but high in MDRs. Results of a meta-analysis study showed that resistance to PZA in non-MDR isolates was up to 9%, but it ranged from 31-- 89% in MDR isolates,[@CIT0050] which is consistent with the current study. PZA is a critical drug, which is active in acidic pH (5 to 5.5) and able to eradicate semidormant forms of MTB. Using PZA, duration of TB treatment shortened from 9--12 months to six months.[@CIT0051],[@CIT0052] Currently, DST in the Mycobacteria Growth Indicator Tube (MGIT) and BACTEC 460 systems are considered as the reference method for PZA susceptibility testing.[@CIT0013] Unfortunately, such systems are not available in resource-limited countries; and they could not routinely perform DST for PZA. The Wayne test is a simple and relatively inexpensive method. Considering the advantages of this method, it could be proposed as alternative method of detection of PZA resistance. It is important to mention that the Wayne test is mainly correlated with the activity of pyrazinamidase enzyme, but other mechanisms might be implicated in the resistance to PZA. Molecular detection of mutations in *pnc*A locus is another method for determining the resistance to PZA that could be used in such condition. Due to the limited number of MDR isolates in this study, future studies using a large number of MDR isolates is necessary for determining the resistance to PZA in MDR isolates circulating in this region.

This study has some limitations. First, we had a limited number of MDR isolates for PZA susceptibility testing and DST for second-line drugs in this study. Second, results for the Wayne test must be confirmed using MGIT960, BACTEC 460 systems or molecular method.

Conclusion {#S0005}
==========

This study showed the presence of highly diverse spoligotyping patterns in Golestan province. The observed genetic diversity of MTBC isolates in this region reflects the role of immigration plus active evolution of isolates circulating in Golestan province. Migration and presence of XDR-TB in this region must be noted as epidemiological and clinical concerns that could be a threat to TB control programs in Iran. Detection of isolates with reduced PZase activity implies the possibility for the presence of initial resistance of MTB isolates recovered from new cases. We recommend further studies for identifying genetic relation between MTBC isolates using whole-genome sequencing method, also such information could be used for detection of mutations responsible for resistance to first- and second-line anti-TB drugs.
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[^1]: **Notes:** Keys; lineage: spoligotype families annotated in SITVITWEB database.

    **Abbreviations:** RMP, Rifampin; INH, Isoniazid; ETL, Ethambutol; STM, Streptomycin; SIT, spoligotype international types; n, number of strains; ■, presence of spacer; □, absence of spacer; O, orphan.
